Literature DB >> 18461364

Levels of VEGF-A mRNA in plasma from patients with colorectal carcinoma as possible surrogate marker of angiogenesis.

Vanesa Garcia1, Jose M Garcia, Javier Silva, Cristina Peña, Gemma Dominguez, Yolanda Lorenzo, Raquel Diaz, Isabel Alonso, Antonio Colas, Alicia Hurtado, Antonio Sanchez, Felix Bonilla.   

Abstract

PURPOSE: The regulator of angiogenesis most extensively studied is VEGF. VEGF mRNA in plasma from patients with colorectal cancer was analyzed as a possible surrogate marker of tumor angiogenesis.
METHODS: VEGF mRNA was measured by quantitative PCR in plasma, tumors and circulating tumor cells from colorectal cancer patients. Circulating VEGF protein was analyzed by ELISA. Microvessel density was determined.
RESULTS: Levels of VEGF mRNA and protein in plasma were higher in patients than in controls. VEGF mRNA was overexpressed in tumors with respect to normal tissues. Levels of VEGF protein were associated with VEGF mRNA in plasma, but no associations with tumor samples were found. A trend to statistical significance was shown between high VEGF mRNA and vascular invasion. MVD was not related to VEGF mRNA in plasma.
CONCLUSIONS: Thus, VEGF mRNA could be a marker similar to VEGF protein in plasma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461364     DOI: 10.1007/s00432-008-0405-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  38 in total

1.  Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma.

Authors:  K W Lo; Y M Lo; S F Leung; Y S Tsang; L Y Chan; P J Johnson; N M Hjelm; J C Lee; D P Huang
Journal:  Clin Chem       Date:  1999-08       Impact factor: 8.327

Review 2.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

3.  Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells.

Authors:  J M Silva; R Rodriguez; J M Garcia; C Muñoz; J Silva; G Dominguez; M Provencio; P España; F Bonilla
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

4.  Telomerase RNA as a detection marker in the serum of breast cancer patients.

Authors:  X Q Chen; H Bonnefoi; M F Pelte; J Lyautey; C Lederrey; S Movarekhi; P Schaeffer; H E Mulcahy; P Meyer; M Stroun; P Anker
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

5.  Microsatellite alterations in plasma DNA of small cell lung cancer patients.

Authors:  X Q Chen; M Stroun; J L Magnenat; L P Nicod; A M Kurt; J Lyautey; C Lederrey; P Anker
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

6.  p53 mutation in plasma DNA and its prognostic value in breast cancer patients.

Authors:  Z M Shao; J Wu; Z Z Shen; M Nguyen
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

7.  Detection of tumor messenger RNA in the serum of patients with malignant melanoma.

Authors:  M S Kopreski; F A Benko; L W Kwak; C D Gocke
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

Review 10.  Vascular endothelial growth factor: basic science and clinical progress.

Authors:  Napoleone Ferrara
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

View more
  3 in total

1.  Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.

Authors:  Axel Grothey; Carmen Allegra
Journal:  Ther Adv Med Oncol       Date:  2012-11       Impact factor: 8.168

2.  The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab.

Authors:  Shu-Dong Zhang; Cian M McCrudden; Chen Meng; Yao Lin; Hang Fai Kwok
Journal:  Onco Targets Ther       Date:  2015-04-15       Impact factor: 4.147

3.  Activation of the PI3K/Akt/mTOR/p70S6K pathway is involved in S100A4-induced viability and migration in colorectal cancer cells.

Authors:  Haiyan Wang; Liang Duan; Zhengyu Zou; Huan Li; Shimei Yuan; Xian Chen; Yunyuan Zhang; Xueru Li; Hui Sun; He Zha; Yan Zhang; Lan Zhou
Journal:  Int J Med Sci       Date:  2014-06-08       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.